Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Galina Salogub, MD PhD, Jiri Mayer, MD, Frantisek Folber, MD PhD, Sebastian Grosicki, MD PhD, Aleksander B Skotnicki, MD PhD, Anna Prochwicz, MD, Alexander Myasnikov, MD, Alexander Gural, MD, Oliver Schoenborn-Kellenberger, MSc, Charlie Brindley, PhD, Stefan Knackmuss, PhD, Sylvia Schwarz, PhD, Sandra Schmich, Cassandra Choe-Juliak, MD MS, Andras Strassz, MD, Leila Alland, MD, Michael Doubek, MD PhD

Blood (2018) 132 (Supplement 1): 3969.

https://doi.org/10.1182/blood-2018-99-118136

Published: 2018

Journal Articles

High Incidence of tMDS in Elderly Lymphoma Patients Subjected to Radioimmunotherapy

Dagmara Zimowska-Curylo, Wojciech Jurczak, Agnieszka Giza, Malgorzata Jakobczyk, Katarzyna Krawczyk, Aleksander B Skotnicki

Blood (2012) 120 (21): 4882.

https://doi.org/10.1182/blood.V120.21.4882.4882

Published: 2012

Journal Articles

Overall Survival (OS) Benefit of Rituximab Based Immunochemotherapy Followed by Post-Induction Treatment in Mantle Cell Lymphoma (MCL): a Retrospective Analysis of 279 Patients Treated by Polish Lymphoma Research Group (PLRG) Centers.

Wojciech Jurczak, Michal Szymczyk, Agnieszka Giza, Monika Joks, Elzbieta Kisiel, Beata Stella-Holowiecka, Piotr Boguradzki, Tomasz Wrobel, Magdalena Sikorska, Wanda Knopinska-Posluszny, Ewa Kalinka-Warzocha, Jan Walewski, Aleksander B. Skotnicki

Blood (2009) 114 (22): 1702.

https://doi.org/10.1182/blood.V114.22.1702.1702

Published: 2009

Journal Articles

Consolidation with Radioimmunotherapy May Prolong Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for Stem Cell Transplantation, An Analysis of the International RIT-Network.

Wojciech Jurczak, MD, Aleksander B. Skotnicki, MD, Andrzej Deptala, MD, Christine Windemuth-Kieselbach, PhD, Michael Lorsbach, Angelika Bischof Delaloye, MD, Suh Cheolwon, MD, Pier Luigi Zinzani, MD, Roberto Cacchione, MD, Werner Linkesch, MD, Francesco d'Amore, MD, Lorenz H. Truemper, MD

Blood (2009) 114 (22): 3746.

https://doi.org/10.1182/blood.V114.22.3746.3746

Published: 2009

Journal Articles

Prognostic Factors in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors- Single Center Experience.

Kajetana Foryciarz, Tomasz Sacha, Izabela Florek, Sylwia Czekalska, Magdalena Zawada, Aleksander B. Skotnicki

Blood (2009) 114 (22): 2210.

https://doi.org/10.1182/blood.V114.22.2210.2210

Published: 2009

Journal Articles

Cladribine in Combination with Standard Daunorubicine and Cytarabine (DAC) as a Remission Induction Treatment Improves the Overall Survival in Untreated Adults with AML Aged < 60 y Contrary to Combination Including Fludarabine (DAF): A Multicenter, Randomized, Phase III PALG AML 1/2004 DAC/DAF/DA Study in 673 Patients-A Final Update.

Blood (2009) 114 (22): 2055.

https://doi.org/10.1182/blood.V114.22.2055.2055

Published: 2009

Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

François Guilhot, Viviane Dubruille, Aleksander B. Skotnicki, Andrey Hellmann, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Elisabetta Abruzzese, Luke Akard

Blood (2008) 112 (11): 4263.

https://doi.org/10.1182/blood.V112.11.4263.4263

Published: 2008

Journal Articles

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Cladribine

Blood (2008) 112 (11): 4179.

https://doi.org/10.1182/blood.V112.11.4179.4179

Published: 2008

Journal Articles

Imatinib Trough Plasma Concentration and Its Correlation with Clinical Response in Chronic Phase and Accelerated Phase of CML

Kajetana Foryciarz, Mathieu Molimard, François-Xavier Mahon, Izabela Florek, Tomasz Sacha, Marcin Sobocinski, Aleksander B. Skotnicki

Blood (2008) 112 (11): 4269.

https://doi.org/10.1182/blood.V112.11.4269.4269

Published: 2008

Journal Articles

Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients

Blood (2008) 112 (11): 133.

https://doi.org/10.1182/blood.V112.11.133.133

Published: 2008

Journal Articles

Survival Benefit of Post Induction Consolidation Therapy in MCL (Mantle Cell Lymphoma): a Polish Lymphoma Research Group (PLRG) Retrospective Multicenter Analysis

Wojciech Jurczak, Agnieszka Giza, Dorota Krochmalczyk, Dagmara Zimowska-Curylo, Marcin Sobocinski, Beata Stella-Holowiecka, Aleksandra Holowiecka-Goral, Piotr Boguradzki, Elzbieta Kisiel, Grzegorz Mazur, Tomasz Wrobel, Wanda Knopinska-Posluszny, Ewa Kalinka - Warzocha, Aleksander B. Skotnicki

Blood (2008) 112 (11): 4936.

https://doi.org/10.1182/blood.V112.11.4936.4936

Published: 2008

Journal Articles

The Reduction of Leukemic Blasts In Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia: The Results of Multicenter, Prospective Polish Adult Leukemia Group Study.

Jerzy Holowiecki, Sebastian Grosicki, Slawomira Kyrcz-Krzemien, Kazimierz Kuliczkowski, Marek Kielbinski, Aleksander B. Skotnicki, Beata Piatkowska-Jakubas, Andrzej Hellmann, MD, PhD, Agnieszka Wierzbowska, Marek Seweryn, Beata Stella-Holowiecka, Maria Sadus-Wojciechowska

Blood (2008) 112 (11): 1950.

https://doi.org/10.1182/blood.V112.11.1950.1950

Published: 2008

Journal Articles

The Reduction of Leukemic Blasts in Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia; the Results of Multicenter, Prospective Polish Adult Leukemia Group Trial.

Jerzy Holowiecki, Sebastian Grosicki, MD, Slawomira Kyrcz-Krzemien, Kazimierz Kuliczkowski, Marek Kielbinski, MD, Aleksander B. Skotnicki, Beata Jakubas, MD, Andrzej Hellmann, Tadeusz Robak, Marek J. Seweryn, MD, Beata Stella-Holowiecka, MD, Maria Sadus-Wojciechowska, MD

Blood (2007) 110 (11): 4375.

https://doi.org/10.1182/blood.V110.11.4375.4375

Published: 2007

Journal Articles

Increased Expression of Pro-Angiogenic and Decreased Expression of Osteogenic Genes by Multipotential Stromal Cells after Stimulation with Myeloma-Derived Microvesicles.

Anna Zebzda, M.Sci., Artur Jurczyszyn, M.D., Ph.D., Danuta Jarocha, M.Sci., Aleksander B. Skotnicki, M.D., Ph.D., Marcin Majka, PhD

Blood (2007) 110 (11): 3515.

https://doi.org/10.1182/blood.V110.11.3515.3515

Published: 2007

Journal Articles

90 Y-Zevalin® ( 90 Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation in Mantle Cell Lymphoma (MCL) Patients, Not Illegible for Intensive Therapy Protocols.

Wojciech Jurczak, Agnieszka Giza, Dagmara Zimowska-Curylo, Alicja Hubalewska-Dydejczyk, Anna Sowa-Staszczak, Wanda Knopinska-Posluszny, Andrzej Hellmann, Barbara Zdziarska, Tomasz Wrobel, Slawomira Krycz-Krzemien, Lidia Poplawska, Jan Walewski, Aleksander B. Skotnicki

Blood (2007) 110 (11): 4497.

https://doi.org/10.1182/blood.V110.11.4497.4497

Published: 2007

Journal Articles

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial

Blood (2007) 109 (9): 3672–3675.

https://doi.org/10.1182/blood-2006-08-042929

Published: 2007

Journal Articles

Comparison of Myeloma Cells Killing Efficiency by Geldanamycin and Its Analogs.

Anna Zebzda, MSci, Artur Jurczyszyn, MD,PhD, Wojciech Czogala, MD, Ewa Lesko, MSci, Jolanta Gozdzik, MD,PhD, Aleksander B. Skotnicki, MD,PhD, Marcin Majka, PhD

Blood (2006) 108 (11): 5027.

https://doi.org/10.1182/blood.V108.11.5027.5027

Published: 2006

Journal Articles

Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.

Blood (2006) 108 (11): 2485.

https://doi.org/10.1182/blood.V108.11.2485.2485

Published: 2006

Journal Articles

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)

Blood (2006) 108 (2): 473–479.

https://doi.org/10.1182/blood-2005-12-4828

Published: 2006

Journal Articles

C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma.

Marcin Majka, PhD, Artur Jurczyszyn, MD, PhD, Anna Zebzda, MSci, Wojciech Czogala, MD, Ewa Lesko, MSci, Zbigniew Rudzki, MD, PhD, Jolanta Gozdzik, MD, PhD, Teresa Wolska-Smolen, MD, PhD, Aleksander B. Skotnicki, MD, PhD, Mariusz Z. Ratajczak, MD, PhD

Blood (2005) 106 (11): 3395.

https://doi.org/10.1182/blood.V106.11.3395.3395

Published: 2005

NARROW

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

High Incidence of tMDS in Elderly Lymphoma Patients Subjected to Radioimmunotherapy

Overall Survival (OS) Benefit of Rituximab Based Immunochemotherapy Followed by Post-Induction Treatment in Mantle Cell Lymphoma (MCL): a Retrospective Analysis of 279 Patients Treated by Polish Lymphoma Research Group (PLRG) Centers.

Consolidation with Radioimmunotherapy May Prolong Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for Stem Cell Transplantation, An Analysis of the International RIT-Network.

Prognostic Factors in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors- Single Center Experience.

A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Cladribine

Imatinib Trough Plasma Concentration and Its Correlation with Clinical Response in Chronic Phase and Accelerated Phase of CML

Survival Benefit of Post Induction Consolidation Therapy in MCL (Mantle Cell Lymphoma): a Polish Lymphoma Research Group (PLRG) Retrospective Multicenter Analysis

The Reduction of Leukemic Blasts In Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia: The Results of Multicenter, Prospective Polish Adult Leukemia Group Study.

The Reduction of Leukemic Blasts in Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia; the Results of Multicenter, Prospective Polish Adult Leukemia Group Trial.

Increased Expression of Pro-Angiogenic and Decreased Expression of Osteogenic Genes by Multipotential Stromal Cells after Stimulation with Myeloma-Derived Microvesicles.

90 Y-Zevalin® ( 90 Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation in Mantle Cell Lymphoma (MCL) Patients, Not Illegible for Intensive Therapy Protocols.

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial

Comparison of Myeloma Cells Killing Efficiency by Geldanamycin and Its Analogs.

Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)

C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only